8-KLeadership ChangesShareholder MattersCorporate Changes+1

DEXCOM INC 8-K Report, Executive Changes (Jun 6, 2017)

Filed June 6, 2017For Securities:DXCM

Summary

This 8-K filing from DexCom, Inc. (DXCM) on June 6, 2017, details key corporate governance actions and stockholder approvals from their Annual Meeting held on May 31, 2017. The most significant updates involve the adoption and stockholder approval of the Amended and Restated 2015 Equity Incentive Plan, which increased the share reserve, and an amendment to the Certificate of Incorporation to double the authorized common stock. Additionally, the company adopted a Severance and Change in Control Plan for its executives, outlining benefits in the event of qualifying terminations during or outside of a change in control period, including accelerated vesting of equity awards. Investors will note the strong support for re-election of directors and ratification of the independent auditor. The advisory vote on executive compensation received majority support, and stockholders approved holding the advisory vote on compensation annually. The expansion of authorized shares is a notable move, potentially indicating future capital needs or strategic initiatives. The implementation of a change-in-control plan suggests a proactive approach to executive retention and alignment during potential corporate transactions.

Key Highlights

  • 1Stockholder approval of the Amended and Restated 2015 Equity Incentive Plan, increasing share availability by 3.6 million shares and eliminating dividend payments on unvested shares.
  • 2Stockholder approval to amend the Certificate of Incorporation to increase authorized common stock from 100 million to 200 million shares.
  • 3Adoption of a Severance and Change in Control Plan for eligible executives, outlining severance benefits, COBRA premium payments, and equity vesting acceleration upon qualifying terminations.
  • 4Election of Richard Collins, Mark Foletta, and Eric J. Topol as Class III directors, each serving until their successor is elected.
  • 5Ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2017 with strong stockholder support.
  • 6Approval of the non-binding advisory resolution on executive compensation with approximately 80% of votes in favor.
  • 7Approval of an annual frequency for the advisory vote on executive compensation, with nearly 88% of votes in favor.

Frequently Asked Questions

The Amended and Restated 2015 Equity Incentive Plan reserves an additional 3,600,000 shares of DexCom's common stock for issuance. This plan was approved by stockholders and also introduced a provision to eliminate dividend payments on unvested shares.

DexCom amended its Certificate of Incorporation to increase the number of authorized shares of Common Stock from 100,000,000 to 200,000,000. This action, approved by stockholders, may be to provide greater flexibility for future financing, acquisitions, stock-based compensation, or other strategic corporate activities.

The plan provides severance benefits to eligible executives upon a 'Qualifying Termination' (involuntary termination or termination for 'Good Reason') within a specified period around a 'Change in Control'. Benefits can include cash severance, a pro-rata bonus, COBRA premium payments, and acceleration of vesting for equity awards. Payments are subject to a waiver and release of claims and may be reduced to avoid 'parachute payment' penalties under Section 280G of the Internal Revenue Code.

The non-binding advisory resolution on executive compensation received strong support, with approximately 80.15% of the votes cast in favor. Stockholders also approved holding this advisory vote on compensation on an annual basis, with nearly 88% of votes supporting an annual frequency.